Ernexa Therapeutics Inc.
ERNA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 755.9% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 83.5% | -247.1% | – | – |
| R&D Expenses | $5 | $6 | $10 | $13 |
| G&A Expenses | $13 | $15 | $17 | $15 |
| SG&A Expenses | $13 | $15 | $17 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | $0 | $6 | $86 |
| Operating Expenses | $16 | $21 | $33 | $114 |
| Operating Income | -$16 | -$21 | -$33 | -$114 |
| % Margin | -2,693.1% | -31,080.9% | – | – |
| Other Income/Exp. Net | -$29 | -$1 | $9 | -$9 |
| Pre-Tax Income | -$45 | -$22 | -$25 | -$122 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$45 | -$22 | -$25 | -$123 |
| % Margin | -7,652.7% | -31,864.7% | – | – |
| EPS | -1.57 | -4.08 | -8.06 | -56.61 |
| % Growth | 61.5% | 49.4% | 85.8% | – |
| EPS Diluted | -1.57 | -4.08 | -8.06 | -56.61 |
| Weighted Avg Shares Out | 28 | 5 | 3 | 2 |
| Weighted Avg Shares Out Dil | 28 | 5 | 3 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $7 | $1 | $0 | $0 |
| Depreciation & Amortization | $2 | $1 | $0 | $0 |
| EBITDA | -$36 | -$20 | -$24 | -$122 |
| % Margin | -6,206% | -29,314.7% | – | – |